Next-generation DNA sequencing technology has dramatically advanced clinical oncology
through the identification of therapeutic targets and molecular biomarkers, leading to the …

In recent years, the rapid development of next-generation sequencing (NGS) technologies
has led to a significant reduction in sequencing cost with improved accuracy. In the area of …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Liquid biopsies, comprising the noninvasive analysis of circulating tumor-derived material
(the 'tumor circulome'), represent an innovative tool in precision oncology to overcome …

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that
originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as …

Precision medicine in the clinical management of cancer may be achieved through the
diagnostic platform called “liquid biopsy”. This method utilizes the detection of biomarkers in …

Background The promise of precision cancer medicine presently centers around the
genomic sequence of a patient's tumor being translated into timely, actionable information to …

Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response
(pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC) …

Lung cancer is the deadliest cancer worldwide. Tissue biopsy is currently employed for the
diagnosis and molecular stratification of lung cancer. Liquid biopsy is a minimally invasive …

Simple Summary The gold standard for detecting cancer and profiling tumors is tissue
biopsies. Despite this, tissue biopsies have been associated with many limitations leading to …